Mizuho lowered the firm’s price target on IN8bio (INAB) to $4 from $60 and keeps an Outperform rating on the shares. The firm continues to believe in IN8bio’s INB-100 program but adjusted the price target to reflect the 1-for-30 reverse stock split.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential